{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-047360","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2023-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.658551+00:00","generated_at":"2026-06-10T21:37:17.180853+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"medium","headline":"aTyr Pharma reports positive Phase 1b/2a post-hoc data for efzofitimod in sarcoidosis","bullets":["Therapeutic doses (3.0 & 5.0 mg/kg) reduced steroid relapse rate to 7.7% vs 54.4% (p=0.017).","FVC rate of change significantly improved for therapeutic vs placebo/subtherapeutic group (p=0.035).","52.9% of therapeutic group achieved ≥12 KSQ-L improvement (3x MCID) vs 15.0% (p=0.032).","64.7% of therapeutic group met composite responder endpoint vs 20.0% (p=0.008)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-047360","json":"https://secwatch.observer/filing/0000950170-23-047360.json","markdown":"https://secwatch.observer/filing/0000950170-23-047360.md","text":"https://secwatch.observer/filing/0000950170-23-047360.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023047360/0000950170-23-047360-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023047360/life-20230910.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T21:37:17.180853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}